Background: Stent implantation activates inflammatory reactions in the coronary tree and perisistent inflammation after coronary stenting predicts adverse outcomes. Sirolimus exerts anti-inflammatory action. While changes in the inflammatory mediators to implantation of bare metal stent (BMS) have been reported, studies on the potential changes in the systemic inflammatory response after implantation of drug-eluting stent (DES) have not. We compared the the systemic inflammatory response after coronary implantatation of BMS or DES in patients with stable angina. Methods: High sensitivity C-reactive protein (hsCRP) and fibrinogen levels were assayed in the serum before, 6 hours, 24 hours, 48 hours, and 14 weeks after stenting in 80 patients with stable angina, who were randomly assigned to receive BMS (BMS group), paclitaxel, or sirolimus-eluting stents (DES groups). Results: Coronary stenting significantly increased the hsCRP levels early (6 hours) after stenting and further rise to peak levels within 48 hours. The variation in the level of hsCRP was comparable among study groups (Fig). In DES groups, the hsCRP levels tended to rise late after stent implantation as compared with BMS group. However, the fibrinogen levels were not significantly increased after stenting. Conclusion: Coronary stent implantation including DES induces a systemic inflammatory response, as reflected in the temporal increase of the hsCRP levels. Anti-inflammatory therapy might be needed to further improve the clinical outcome after coronary implantation of stent, even DES.